Illumina Inc ILMN

Morningstar Rating
$273.04 +7.32 (2.75%)
View Full Chart

Company Report

Illumina Looks Likely To Benefit From AI Initiatives in Life Sciences

Illumina continues to focus on transforming human health practices through its leadership of genomic sequencing and related applications. The firm provides a broad range of instruments and related consumables to help researchers and clinicians identify and understand genetic variations. The scale of these projects can be wide, such as population genomic initiatives being pursued in many countries, or narrow, such as noninvasive prenatal screening. We believe Illumina will continue to benefit from the rapidly expanding applications of genomic sequencing tools through its own innovation and select acquisitions.

Price vs Fair Value

ILMN is trading at a LOCK|W^%$@>b premium.
Price
$265.72
Fair Value
tmz
Uncertainty
LOCK|Lp
1-Star Price
LOCK|^.%%
5-Star Price
%j&
Economic Moat
LOCK|F&c^g
Capital Allocation
LOCK|JF?SW%@

Bulls Say, Bears Say

Bulls

Genomic sequencing remains a relatively early stage market, and expanding sequencing indications, including the nascent liquid biopsy applications that would use its sequencers, create large growth opportunities for Illumina even without owning all of Grail.

Bears

Disruptive technology risks could threaten Illumina's industry-leading sequencing platform, leading to market share losses.

News

Articles & Videos

Trading Information

Previous Close Price
$265.72
Day Range
$265.39–274.97
52-Week Range
$88.00–280.17
Bid/Ask
$266.66 / $277.73
Shares Outstanding
151.00M
Market Cap
$41.23B
Volume/Avg
3M / 3M

Key Statistics

Price/Earnings (Normalized)
51.60
Price/Sales
9.11
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Dividend Payment Schedule
—
Total Yield
1.25%

Company Profile

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina’s high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Sector
Healthcare
Industry
Diagnostics & Research
Stock Style Box
Mid Growth
Total Number of Employees
8,650

Competitors

Valuation

Metric
ILMN
TMO
Price/Earnings (Normalized)
51.6027.38
Price/Book Value
14.144.58
Price/Sales
9.115.28
Price/Cash Flow
31.5524.07
Price/Earnings
ILMN
TMO

Financial Strength

Metric
ILMN
TMO
Quick Ratio
1.221.01
Current Ratio
1.801.55
Interest Coverage
10.965.57
Quick Ratio
ILMN
TMO

Profitability

Metric
ILMN
TMO
Return on Assets (Normalized)
6.73%8.26%
Return on Equity (Normalized)
16.79%17.21%
Return on Invested Capital (Normalized)
9.37%10.33%
Return on Assets
ILMN
TMO

Diagnostics & Research Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Thermo Fisher Scientific Inc
TMO
LOCK|G^Wyy>mLOCK|z@W$241B
Danaher Corp
DHR
LOCK|g%L<@W^LOCK|&G>$149B
Agilent Technologies Inc
A
LOCK|jBRB%b@LOCK|$@$47B
IQVIA Holdings Inc
IQV
LOCK|qG!r#WLOCK|KF!r$43B
Waters Corp
WAT
LOCK|fN$j!QsLOCK|yX$42B
IDEXX Laboratories Inc
IDXX
LOCK|fGJ$>#$jLOCK|bhH$41B
Mettler-Toledo International Inc
MTD
LOCK|!p@x#v%YLOCK|$##q$30B
Quest Diagnostics Inc
DGX
LOCK|q?MT^DtLOCK|vR@Yc$26B
Labcorp Holdings Inc
LH
LOCK|P!g^k?@jLOCK|jDw@$25B

Sponsor Center